JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.
There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.
An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JANUVIA prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUVIA.
There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal impairment, some of whom were prescribed inappropriate doses of sitagliptin.
Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with end-stage renal disease requiring hemodialysis or peritoneal dialysis.
When JANUVIA was used in combination with insulin or insulin secretagogues
(eg, sulfonylurea), medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.
The incidence (and rate) of hypoglycemia based on all reports of symptomatic hypoglycemia were: 12.2% (0.59 episodes/patient-year) for JANUVIA 100 mg in combination with glimepiride (with or without metformin), 1.8% (0.24 episodes/patient-year) for placebo in combination with glimepiride (with or without metformin), 15.5%
(1.06 episodes/patient-year) for JANUVIA 100 mg in combination with insulin (with or without metformin), and 7.8% (0.51 episodes/patient-year) for placebo in combination
with insulin (with or without metformin).
There have been postmarketing reports of serious hypersensitivity reactions in
patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin
conditions including Stevens-Johnson syndrome. Onset of these reactions occurred
within the first 3 months after initiation of treatment with JANUVIA, with some reports
occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue
JANUVIA, assess for other potential causes for the event, and institute alternative
treatment for diabetes.
Angioedema has also been reported with other DPP-4 inhibitors. Use caution in
a patient with a history of angioedema with another DPP-4 inhibitor because it is
unknown whether such patients will be predisposed to angioedema with JANUVIA.
There have been postmarketing reports of severe and disabling arthralgia in patients
taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug
therapy varied from 1 day to years. Patients experienced relief of symptoms upon
discontinuation of the medication. A subset of patients experienced a recurrence of
symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider
DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if
appropriate.
Postmarketing cases of bullous pemphigoid requiring hospitalization have been
reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with
topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving
JANUVIA. If bullous pemphigoid is suspected, JANUVIA should be discontinued
and referral to a dermatologist should be considered for diagnosis and appropriate
treatment.
In clinical studies, the adverse reactions reported, regardless of investigator
assessment of causality, in ≥5% of patients treated with JANUVIA as monotherapy
and in combination therapy and more commonly than in patients treated with placebo,
were upper respiratory tract infection, nasopharyngitis, and headache.
Important Information
JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
JANUVIA should not be used in patients with type 1 diabetes.
JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.
Before prescribing JANUVIA, please read the accompanying Prescribing
Information. The Medication Guide also is available.
Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
US-DIA-02602 06/23